← Back to Clinical Trials
Recruiting NCT06497296

NCT06497296 The Optimal Timing of the Initiation of Esophagogastroduodenoscopy After Oral Lidocaine Spray

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06497296
Status Recruiting
Phase
Sponsor National Cheng-Kung University Hospital
Condition Blood Pressure
Study Type INTERVENTIONAL
Enrollment 160 participants
Start Date 2023-01-01
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Lidocaine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 160 participants in total. It began in 2023-01-01 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Esophagogastroduodenoscopy (EGD) is the main examination in the upper gastrointestinal field. Aspiration pneumonia may happen if choking occurs during the EGD insertion, and the exam quality and efficacy may be affected if gag reflex occurs. The endoscopist may terminate the exam to avoid complications if the patient could not obey the orders. To reach the high quality of EGD examination and to avoid possible complications, the patient's comfort and compliance during the EGD examination are important. Sedation using propofol can improve the patient's comfort and compliance. However, in patients unsuitable for systemic anesthesia, local lidocaine spray at pharynx is performed instead. Until now, there is no standardization of the waiting time between lidocaine spray and the initiation of EGD. This study aimed to investigate the optimal timing of the initiation of esophagogastroduodenoscopy after lidocaine spray.

Eligibility Criteria

Inclusion Criteria: * Eligible participants included patients aged ≥ 20 years who scheduled EGD from OPD for dyspepsia, peptic ulcer disease, GERD, subepithelial lesion evaluation, and diarrhea Exclusion Criteria: * GI bleeding * endoscopic submucosal dissection due to prolonged scheduled procedure time * patients from emergency department or ward

Contact & Investigator

Central Contact

Hsueh-Chien Chiang, M.D.

✉ scion456scion@gmail.com

📞 062353535

Frequently Asked Questions

Who can join the NCT06497296 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 90 Years, studying Blood Pressure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06497296 currently recruiting?

Yes, NCT06497296 is actively recruiting participants. Contact the research team at scion456scion@gmail.com for enrollment information.

Where is the NCT06497296 trial being conducted?

This trial is being conducted at Tainan, Taiwan.

Who is sponsoring the NCT06497296 clinical trial?

NCT06497296 is sponsored by National Cheng-Kung University Hospital. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology